Kornimate/medical-research-clean huggingface dataset:
study to evaluate home vision testing in participants who receive ranibizumab (lucentis®)

Conditions: Macular Edema; Macular Degeneration

Summary: this pilot study will evaluate home vision testing using a mobile medical application in participants with diabetic macular edema (dme) or neovascular age-related macula degeneration (namd) who receive intravitreal ranibizumab therapy. in the main, decentralized study, participants will be recruited via digital media, advocacy groups, or through their own ophthalmologist. the traditional substudy will evaluate the association between visual acuity and anatomical markers of disease status determined using clinical "gold standard" assessments (certified early treatment diabetic retinopathy study \[etdrs\] protocol visual acuity and macula optical coherence tomography \[oct\]) and the results of home vision testing using the myvisiontrack\^tm (mvt) application.


Eligibility criteria:
inclusion criteria: * dme or active namd in at least one eye * current treatment with intravitreal ranibizumab therapy, with evaluations planned every 4 to 8 weeks * access to an approved mobile device with a data plan or wifi internet access exclusion criteria: * any other eye condition causing eye disease that limits vision and cannot be corrected, other than dme or namd * dementia or other neurologic or psychological limitation that would prevent the participant from performing regular self-testing of visual function
parachute v percutaneous ventricular restoration in chronic heart failure due to ischemic heart disease.

Conditions: Heart Failure; Left Ventricular Dysfunction

Summary: prospective, multi-center, post-market, non-randomized, nested-control, observational study of the ce marked cardiokinetix parachute implant system.

prospective, multi-center, post-market, non-randomized, nested-control, observational study of the european conformity approved (ce marked) cardiokinetix parachute implant system. the primary objective is to establish quality-of-life and cardiac output benefit of the parachute implant of patients presenting with symptoms of heart failure due to ischemic heart disease. a maximum of 105 treated patients and approximately 25 control patients may be enrolled, with a maximum of 25 treated patients enrolled from any one center. the primary endpoint is an improvement of quality of life of patients treated with the parachute implant at 6 months compared to baseline using the minnesota living with heart failure (mlwhf) questionnaire. the secondary endpoint is an improvement in stroke volume index (ml/m2) of patients treated with the parachute implant at post-procedure compared to pre-procedure.

Eligibility criteria:
inclusion criteria: * post mi structural heart dysfunction represented by left ventricular (lv) wall motion abnormality (wma) * symptomatic heart failure with reduced ejection fraction (ef) (≤ 40%) * receiving stable medication for heart failure according to the european society of cardiology (esc) heart failure (hf) guidelines * \>18 years of age * provide written informed consent * agree to the protocol-required follow-up exclusion criteria: * acute myocardial infarction (mi) of the left anterior descending territory within 90 days of enrollment or patients with suspected evolving mi at time of enrollment * cardiogenic shock within 72 hours of enrollment * a known hypersensitivity or contraindication to aspirin, warfarin, nitinol (titanium and nickel alloy), or sensitivity to contrast media, which cannot be adequately pre medicated * other hemodynamically structural heart interventions or heart failure device treatment at time of parachute implant, e.g. mitral valve clip or cardiac resynchronization therapy). * co-morbidities associated with a life expectancy of less than 12-months * treatment arm only (control arm excluded from this criteria): anatomical characteristics not suitable for treatment with the parachute implant device as screened by magnetic resonance imaging (mri) or computerized tomography (ct). (characteristics include inappropriate size and shape of the left ventricle, pseudo chordae or trabeculations interfering with device placement.)

Keywords: heart failure parachute partitioning device
the effect of patellar taping and isometric strength training on quadriceps strength with patellofemoral pain syndrome.

Conditions: Patello Femoral Syndrome

Summary: patellofemoral pain syndrome is one of the most common young adult female complaints, caused by changes in the patellofemoral joint's physical and biomechanical properties. this study compared the short-term effects of patellar taping combined with isometric contraction of quadriceps muscle strengthening at 900 or 600 knee angles on quadriceps strength and functional performance in a female patient with patello-femoral pain syndrome (pfps)

quadriceps muscle strength pain intensity knee function

Eligibility criteria:
inclusion criteria: * knee pain for at least eight weeks that was aggravated by activities such as descending and ascending stairs, squatting, and running. * knee pain with a positive j sign (lateral tilt of patella) * more symptomatic and mal align knee included in case of bilateral involvement and a sign of patellar malalignment on the radiograph. exclusion criteria: * history of knee fracture * patella dislocation * knee deformity (e.g., genu varum) * knee flexion contracture * ligament/meniscal injuries, * nsaid or intra-articular injection, or knee osteo arthritis.

Keywords: patello-femoral pain syndrome pain strength maximum voluntary isometric contraction (mvic).
causality of poisoning of the elderly: prospective study based on data from the poison control centre of bordeaux

Conditions: Intoxication

Summary: elderly is often associated with social, physiological and psychic changes. however, no study has examined accidental poisoning-induced changes. the objective of the study is to identify and analyze the various causes of potentially toxic accidental exposure of the elderly to determine preventable causes and propose prevention strategies.

elderly is often associated with social, physiological and psychic changes. many studies tried to demonstrate their influence in the genesis of pathological events such as falls or suicide of the elderly but none on the genesis of accidental poisoning. however, poisoning in this age group is frequent and sometimes severe. in order to improve care of the elderly, it seems necessary to focus on potential toxic accidental exposure. for this, poison control centre of the university hospital of bordeaux has identified the causes over a period of 5 months (from 01 march to 31 july 2017) from calls to the centre.

Eligibility criteria:
inclusion criteria: * all subjects aged 65 and over, * victims of accidental exposure regardless of the agent (drug, household product, plant ...) * victims of voluntary exposure (out of suicidal behavior) * and for which a call (notice, report) to the poison control centre of bordeaux has been recorded. * calling dates between march 1st and july 31st, even if the exhibition is prior to march 1st, 2017). exclusion criteria: * suicide * calls for inquiries

Keywords: elderly intoxication poison control centre poisoning accidental exposure prevention
effects of dietary supplement tauroursodeoxycholic acid on vascular function

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of the present study is to determine if use of dietary supplement tauroursodeoxycholic acid enhances insulin-stimulated leg blood flow and glucose disposal.

the notion that cellular stress lowers insulin-induced vasodilation is largely founded on ex vivo studies and experiments in rodents. however, it remains unknown if maintenance of cellular function with the use of dietary supplement tauroursodeoxycholic acid enhances vascular function in humans. the investigators test the hypothesis that daily administration of this dietary supplement enhances vascular function, particularly, insulin-stimulated leg blood flow and glucose disposal.

Eligibility criteria:
inclusion criteria: * type 2 diabetes diagnosed by primary physician * body mass index less then 43 kg/m2 exclusion criteria: * recent weight gain or loss (\>5% body weight in the last 3 months) * pregnancy * consumption of \>14 alcoholic beverages per week * changes in the medication use or dose within the last 3 months * known cardiovascular or pulmonary disease * taking medication for advanced retinopathy or neuropathy * taking prescription anticoagulants * nicotine use
pre- vs. postoperative scalp block for pain control after supratentorial craniotomy

Conditions: Supratentorial Neoplasms

Summary: study was designed to evaluate optimal timing for selective scalp block in patients undergoing general anesthesia for supratentorial craniotomy.pain score assessed by visual analog scale (vas) preoperatively (baseline) and after extubation at 2, 6, 12 and 24 hours; time first request of a patient for rescue analgesia; intraoperative anesthetics and opioids consumption; awakening time; perioperative complications.


Eligibility criteria:
inclusion criteria: * adult patients (\>18 years), * presenting with supratentorial brain tumors scheduled for elective craniotomy under general anesthesia exclusion criteria: * history of allergic reactions on local anesthetics; * asa status ≥ 3; * depressed consciousness in pre- or postoperative period; * aphasia (as investigators were not able to obtain vas score).
no need for neuromuscular blockade in daycase laparoscopic surgery

Conditions: Cholecystitis; Inguinal Hernia, Direct; Umbilical Hernia

Summary: this study analyse the need for neuromuscular blockade in consecutive routine laparoscopic procedures without standard use of neuromuscular blockade in an ambulatory laparoscopic surgery setting and analyse specific reasons for using neuromuscular blockade in individual patients. furthermore, the study report the analgesic use in postoperative care unit and the discharge rate.

the study is retrospective, including consecutive patients in an unrestricted referral of patients undergoing laparoscopic cholecystectomy, umbilical and inguinal hernia repair. inclusion period was from 01.04.2013 to 31.03.2015. all patients received general anesthesia using propofol (2 mg/kg) and remifentanil (1 μg/kg/min) for induction. in patients where tracheal intubation was required, this was done without use of neuromuscular blocking drug; otherwise a proseal laryngeal mask was used. for the maintenance of anesthesia, additional continuous infusion of propofol (3-5 mg/kg/h) and remifentanil (0.3-0.5 μg/kg/min) was used. data were derived from a prospective local database on demographics, anesthetic methods and supplements (i.e. need for neuromuscular blockade) and postoperative needs for supplementary analgesics besides the postoperative standard analgesic regimen, number of hours stayed in the ambulatory surgery department, and discharge rate (including reasons for hospital admittance).

Eligibility criteria:
inclusion criteria: * patients undergoing laparoscopic cholecystectomy, umbilical and inguinal hernia repair exclusion criteria: * none

Keywords: neuromuscular blockade surgery
in vitro functional modulation of monocyte-derived dendritic cells of patients with cancer by peptides

Conditions: Metastatic Cancer

Summary: the purpose of this study is to evaluate in vitro the potential of peptides, to modify, phenotypically and functionally, the monocyte-derived dendritic cells of patients with metastatic cancer.

the dcs will be generated in vitro from peripheral blood mononuclear cells (pbmcs) which will be obtained from 30 ml of peripheral blood collected from each patient with metastatic cancer by venipuncture in heparin tubes. the cellular viability, the expression of maturation biomarkers and the presence of several cytokines will be evaluated by flow cytometric assays after the culture period of dcs exposed to the peptides. an interim analysis is programmed with the first 10 patients. if an effect is demonstrated the study will include an additional number of subjects sufficient to ensure adequate comparison with other commercially available peptides.

Eligibility criteria:
inclusion criteria: 1. signature of the informed consent form before the performing of any procedures related to the study; 2. age ≥18 years; 3. histologically confirmed metastatic malignant neoplasia; 4. results of laboratorial exams in the first 6 weeks before the blood sample collection within the following values: * white blood cells ≥ 3.000/μl; * platelet count ≥ 100,000/mm³; * hemoglobin \> 10g/dl; * serum aspartate aminotransaminase (ast), alanine aminotransferase (alt) and alkaline phosphatase \< 2.5 x upper limit of normal (uln); * serum creatinine \< 1.5 x upper limit of normal (uln); 5. karnofsky performance status ≥ 70%. exclusion criteria: 1. presence of autoimmune disorders or conditions that require systemic treatment with immunosuppressant medications or systemic corticosteroids; 2. received any systemic chemotherapy or radiotherapy within 15 days prior to the blood sample collection; 3. received any immunotherapy within 4 weeks prior to the blood sample collection; 4. known history of positive serology for hiv (human immunodeficiency virus).

Keywords: cancer in vitro peptides dendritic cells
efficacy, safety, and tolerability of eslicarbazepine acetate in the recurrence prevention of bipolar i disorder

Conditions: Bipolar I Disorder

Summary: this was an extension study consisting of 2 parts. in part i, all participants received open-label treatment with bia 2-093 900 mg once daily for 2 weeks. part ii followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with bia 2-093 300 mg, 900 mg, or 1800 mg once daily. patients stable in remission continued double-blind therapy until approximately 6 months after the last patient entered part ii.

the occurrence of a new manic/depressive episode was considered a treatment failure, and the patient was discontinued from the study. at the end of part ii, 6 months after last patient enrolled and after no longer than approximately 15 months, if patients were still in remission and the investigational product was well-tolerated, patients had the option to enter long-term open-label treatment at the same dosage as used in part ii until a new episode occurred, until marketing was authorized, or until clinical development of bia 2-093 in the recurrence prevention indication was discontinued. if patients did not enter long-term treatment, an established recurrence prevention medication was prescribed, and bia 2-093 was tapered off (patients assigned to 1800 mg had the daily dose decreased to 900 mg for 6 days; those assigned to 900 mg or 300 mg received placebo for 6 days).

Eligibility criteria:
inclusion criteria: * signed the informed consent form (icf) * completed the 3-week treatment period in protocol with identification number sco/bia-2093-203 or protocol with identification number pra/bia-2093-204 and shown response to treatment, defined as ≥ 50% improvement in the young mania rating scale (ymrs) total score or a ymrs total score \< 12 * presented a serum pregnancy test (in cases of women of childbearing potential) consistent with a non-gravid state and used double-barrier contraception throughout the study exclusion criteria: * relevant electrocardiogram (ecg) or laboratory abnormalities * any uncontrolled clinically relevant disorder * uninsured capability to comply with the study protocol

Keywords: bipolar i disorder eslicarbazepine acetate bia 2-093
best incision in cesarean section of obese women

Conditions: Morbid Obesity; Cesarean Section Complications

Summary: the goal of this comparative clinical trial is to compare pfannenstiel incision and higher transverse supra umbilical incision techniques during elective cesarean section in morbidly obese patients. the main questions it aims to answer are: is there a difference in operative time between the two incision techniques? is there a difference in estimated blood loss between the two techniques? is there a difference in post-operative pain scores between the two techniques? is there a difference in wound complication rates between the two techniques? participants will be randomly assigned to receive either a pfannenstiel incision or a higher transverse supra umbilical incision during their scheduled cesarean delivery. researchers will compare the pfannenstiel incision group to the higher transverse supra umbilical incision group to see if there are differences in operative time, blood loss, post-operative pain, and wound complications.

this randomized controlled trial will enroll 60 morbidly obese pregnant patients scheduled for elective cesarean delivery at gestational age ≥37 weeks. morbid obesity will be defined as pre-pregnancy body mass index ≥40 kg/m2. patients will be randomly allocated to one of two groups (30 patients per group): group 1 (pfannenstiel group): patients will undergo a transverse infraumbilical skin incision 2-3 cm above the symphysis pubis, followed by transverse incision of the anterior rectus sheath in the same line as the skin incision, blunt digital separation of the rectus muscles, and transverse uterine incision in the lower segment. group 2 (supra-umbilical transverse group): patients will undergo a transverse skin incision halfway between the umbilicus and xiphoid process, followed by transverse incision of the anterior rectus sheath in the same line, blunt digital separation of the rectus muscles, and transverse uterine incision in the lower segment. the primary outcome measures will be operative time, estimated blood loss, post-operative pain scores, and wound complication rates. secondary outcomes will include length of hospital stay, patient satisfaction scores, and cosmetic results.

Eligibility criteria:
inclusion criteria: * female patients aged between 20 and 40 years. * singleton pregnancy. * gestational age ≥ 37 weeks. * scheduled for elective cesarean delivery. * morbid obesity, defined as pre-pregnancy body mass index (bmi) ≥ 40 kg/m2. * willing and able to provide informed consent. * able to adhere to study procedures and follow-up schedule. exclusion criteria: * emergency cesarean delivery. * multiple gestation (twins, triplets, etc) * placenta previa or vasa previa. * history of more than 1 previous cesarean delivery. * hiv, hepatitis b/c infection. * current anticoagulation therapy. * immune-compromised conditions. * premature rupture of membranes. * pre-existing skin conditions affecting the abdomen. * inability to provide informed consent.

Keywords: elective cesarean section morbid obesity pfannenstiel incision transverse supra-umbilical incision
zoledronic acid to maintain bone mass after denosumab discontinuation

Conditions: Postmenopausal Osteoporosis

Summary: in contrast with bisphosphonates,discontinuation of denosumab results in gradual loss of bone mineral density gains. the investigators aim to evaluate whether in patients treated with denosumab, a single zoledronic acid infusion would prevent the anticipated bone loss.

discontinuation of denosumab results in a rebound rise of bone turnover markers and gradual loss of the achieved bone mineral density gains. in contrast, bisphosphonates, such as zoledronic acid, remain within the skeleton acting for several months or even years after discontinuation while maintaining bone mineral density despite the cessation of treatment. in this study, the investigators aim to evaluate changes in bone mineral density of the lumbar spine and the femoral neck, as well as in bone turnover markers one year after treatment discontinuation both in denosumab-treated women and in denosumab-treated women who switched to zoledronic acid infusion one year before treatment discontinuation.

Eligibility criteria:
inclusion criteria: * postmenopausal women * osteopenic (t-score \> -2.5 but \< -1.0) after treatment with denosumab exclusion criteria: * secondary osteoporosis; * diseases that could affect bone metabolism; * medications that could affect bone metabolism; * history of any antiosteoporotic treatment other than denosumab prior to randomization * severe liver or kidney disease (creatinine clearance \< 60ml/min/1.73m2)

Keywords: osteoporosis denosumab zoledronic acid bone mineral density bone markers
acupuncture treatment for active crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this study is to observe the efficacy and safety of acupuncture and moxibustion for crohn's disease and the regulation mechanism of intestinal microbiota and peripheral immunity.

1. a randomized controlled trial. 2. acupuncture and moxibustion treatment, placebo control. 3. to observe the efficacy and safety of acupuncture and moxibustion treatment versus placebo controlled for crohn's disease. 4. to observe the effect on the regulation of intestinal microbiota in crohn's disease. 5. to observe the effect on the regulation of peripheral immunity in crohn's disease. 6. to observe the effect on the regulation of brain function and structure in crohn's disease.

Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria of crohn's disease; 2. age 16-70 years old; 3. patients with mild or moderate disease (150\<cdai\<450) and evidence of active inflammation: serum c-reactive protein concentration ≥5 mg/l, fecal calprotectin concentration ≥250 μg/g, or obvious endoscopic evidence of ulcerations during the screening period of past 4 weeks; 4. patients who were not responsive, intolerant, dependent, or refused to use any one of the following medications: mesalazine, glucocorticoid, immunomodulator (azathioprine, methotrexate), and anti-tnf-α agents; 5. did not take or take one or more of the following drugs: prednisone \<15 mg/d for at least one month, azathioprine (\<1 mg/kg/d), methotrexate (\<15 mg/week), or mesalazine (\<4 g/d) for at least 3 months; 6. no history of use of anti-tnf-alpha or other biological agents within 3 months immediately preceding the enrolment in the study; 7. no previous history of receiving acupuncture; 8. provision of written informed consent. exclusion criteria: 1. pregnant or lactating women, and those desirous of conceiving in the near future; 2. patients with severe organic diseases; 3. patients with mental illness; 4. patients receiving antibiotics, probiotics, prebiotics, traditional chinese medicine, or other drugs; 5. patients with multiple comorbid conditions that require long-term therapy with drugs, which may affect the outcome measures; 6. patients with severe extraintestinal manifestations, such as severe skin diseases, eye diseases, or thromboembolic diseases; 7. severe intestinal fistula, abdominal abscess, intestinal stenosis and intestinal obstruction, perianal abscess, gastrointestinal bleeding, bowel perforation, or other complications; 8. patients with short bowel syndrome; 9. patients with a history of abdominal or gastrointestinal surgery in the past six months; 10. patients with skin diseases or defects at the sites of acupuncture that prevents the application of acupuncture.

Keywords: acupuncture moxibustion intestinal microbiota peripheral immunity brain functional and structural changes
defining pet / ct protocols with optimized f18-fdg (fluorodeoxyglucose) dose, focusing on reduced radiation dose and improved image quality

Conditions: Malignant Neoplasm of Breast; Hodgkin Disease; Non-Hodgkin Lymphoma, Follicular (Nodular); Malignant Neoplasm of Bronchus and Lung; Malignant Neoplasm of Colon; Secondary Neoplasm Malignant and Unspecified Lymph Nodes; Malignant Melanoma of the Skin; Malignant Neoplasm of Small Intestine

Summary: identify the best combination of predictive variables that influence ionizing radiation dose and improved image quality through analysis and quantification of pet-ct images in simulators and patients.


Eligibility criteria:
inclusion criteria: * healthy volunteers; * both genders; * age over 18 years; * clinical indication for pet-ct scan. exclusion criteria: * pregnant women; * patients who have lesions in the liver metabolically active whether primary or metastatic; * patients with movement difficulties.